Delivery Order SPE2DR25D3304-SPE2DR26F47P0
Award Date 11/13/25
Potential Completion Date 11/14/25
Potential Value $16K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a $15,863.44 delivery order to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL, a biologic immunosuppressant medication commonly used to treat rheumatoid arthritis and other autoimmune conditions. The contract utilizes firm fixed pricing with no set-aside designation and is scheduled for completion by November 13, 2025. The pharmaceutical product will be delivered to the company's facility in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 21, 2025, for the supply of HUMIRA (adalimumab) pen 40 mg/0.4 mL, a biologic immunosuppressant medication used to treat rheumatoid arthritis and other inflammatory conditions. This firm fixed-price delivery order, valued at $3,770.00, represents a non-set-aside competitive award and is scheduled for completion by April 22, 2025. The product will be performed at AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $37,698.62 to AmerisourceBergen Drug Corp for the supply of HUMIRA (Adalimumab) Pen 40 mg/0.4 mL, a biologic pharmaceutical used to treat autoimmune conditions. This firm fixed-price delivery order was competitively awarded without set-aside designation and has an ultimate completion date of May 21, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,193.97 to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) CF Pen 40 mg/0.4 mL on November 14, 2025, with completion expected by November 17, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HUMIRA is a widely used biologic immunosuppressant medication prescribed for autoimmune...
- The Defense Logistics Agency awarded a delivery order valued at $1,953.33 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) Pen 40 mg/0.4 mL, a biologic immunosuppressant medication used to treat autoimmune conditions. The contract is a firm fixed-price delivery order with an ultimate completion date of September 24, 2025, and was awarded on a competitive, non-set-aside basis. Performance will take place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency awarded a delivery order valued at $53,776.82 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) pen 40 mg/0.4 mL, a biologic medication used primarily for rheumatoid arthritis and other autoimmune conditions. This firm fixed-price delivery order, awarded on September 9, 2025, with an ultimate completion date of September 10, 2025, represents a non-competitive set-aside procurement conducted under the company's existing Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $2,265.90 to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mls on September 4, 2025, with an ultimate completion date of September 5, 2025. This competitively awarded, firm fixed-price delivery order was placed with no set-aside designation and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. HUMIRA (adalimumab) is a widely-used biologic immunosuppressant medication indicated for...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,643.55 to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) CF Pen 40 mg/0.4 mL on September 9, 2025, with an ultimate completion date of September 10, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania. The contract represents a pharmaceutical supply fulfillment supporting...
- AmerisourceBergen Drug Corp has been awarded a delivery order by the Defense Logistics Agency Medical Supply Chain for $34,644.30 to supply HUMIRA (adalimumab) CF Pen 40 mg/0.4 mL, a biologic immunosuppressant medication used to treat rheumatoid arthritis and other autoimmune conditions. The award, issued on July 15, 2025, with completion targeted for July 16, 2025, employs a firm fixed price structure with no set-aside designation, indicating competitive award selection. The contract will be...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of HUMIRA (adalimumab) Pen 40 mg/0.4 mL, a biologic immunosuppressant medication commonly used to treat rheumatoid arthritis, psoriasis, and other autoimmune conditions. This competitively awarded, non-set-aside delivery order carries a firm fixed price ceiling value of $3,021.20 with an ultimate completion date of August 25, 2025. The contract will be performed at...